<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>56</viewCount><searchCount>0</searchCount></scores><additional><submitter>Wang S</submitter><funding>Suzhou Key Laboratory for Molecular Cancer Genetics</funding><funding>National Natural Science Foundation of China (NSFC)</funding><funding>Academic Program Development of Jiangsu Higher Education Institutions (PAPD)</funding><pagination>e52079</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8183405</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>22(6)</volume><pubmed_abstract>Quaking (QKI) proteins belong to the signal transduction and activation of RNA (STAR) family of RNA-binding proteins that have multiple functions in RNA biology. Here, we show that QKI-5 is dramatically decreased in metastatic lung adenocarcinoma (LUAD). QKI-5 overexpression inhibits TGF-β-induced epithelial-mesenchymal transition (EMT) and invasion, whereas QKI-5 knockdown has the opposite effect. QKI-5 overexpression and silencing suppresses and promotes TGF-β-stimulated metastasis in vivo, respectively. QKI-5 inhibits TGF-β-induced EMT and invasion in a TGFβR1-dependent manner. KLF6 knockdown increases TGFβR1 expression and promotes TGF-β-induced EMT, which is partly abrogated by QKI-5 overexpression. Mechanistically, QKI-5 directly interacts with the TGFβR1 3' UTR and causes post-transcriptional degradation of TGFβR1 mRNA, thereby inhibiting TGF-β-induced SMAD3 phosphorylation and TGF-β/SMAD signaling. QKI-5 is positively regulated by KLF6 at the transcriptional level. In LUAD tissues, KLF6 is lowly expressed and positively correlated with QKI-5 expression, while TGFβR1 expression is up-regulated and inversely correlated with QKI-5 expression. We reveal a novel mechanism by which KLF6 transcriptionally regulates QKI-5 and suggest that targeting the KLF6/QKI-5/TGFβR1 axis is a promising targeting strategy for metastatic LUAD.</pubmed_abstract><journal>EMBO reports</journal><pubmed_title>Quaking 5 suppresses TGF-β-induced EMT and cell invasion in lung adenocarcinoma.</pubmed_title><pmcid>PMC8183405</pmcid><funding_grant_id>SZS201209</funding_grant_id><funding_grant_id>81872343</funding_grant_id><funding_grant_id>81672277</funding_grant_id><pubmed_authors>Jin E</pubmed_authors><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Li C</pubmed_authors><pubmed_authors>Lei Z</pubmed_authors><pubmed_authors>Zhang HT</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Tong X</pubmed_authors><pubmed_authors>Su Z</pubmed_authors><pubmed_authors>Sun Z</pubmed_authors><view_count>56</view_count></additional><is_claimable>false</is_claimable><name>Quaking 5 suppresses TGF-β-induced EMT and cell invasion in lung adenocarcinoma.</name><description>Quaking (QKI) proteins belong to the signal transduction and activation of RNA (STAR) family of RNA-binding proteins that have multiple functions in RNA biology. Here, we show that QKI-5 is dramatically decreased in metastatic lung adenocarcinoma (LUAD). QKI-5 overexpression inhibits TGF-β-induced epithelial-mesenchymal transition (EMT) and invasion, whereas QKI-5 knockdown has the opposite effect. QKI-5 overexpression and silencing suppresses and promotes TGF-β-stimulated metastasis in vivo, respectively. QKI-5 inhibits TGF-β-induced EMT and invasion in a TGFβR1-dependent manner. KLF6 knockdown increases TGFβR1 expression and promotes TGF-β-induced EMT, which is partly abrogated by QKI-5 overexpression. Mechanistically, QKI-5 directly interacts with the TGFβR1 3' UTR and causes post-transcriptional degradation of TGFβR1 mRNA, thereby inhibiting TGF-β-induced SMAD3 phosphorylation and TGF-β/SMAD signaling. QKI-5 is positively regulated by KLF6 at the transcriptional level. In LUAD tissues, KLF6 is lowly expressed and positively correlated with QKI-5 expression, while TGFβR1 expression is up-regulated and inversely correlated with QKI-5 expression. We reveal a novel mechanism by which KLF6 transcriptionally regulates QKI-5 and suggest that targeting the KLF6/QKI-5/TGFβR1 axis is a promising targeting strategy for metastatic LUAD.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2022-02-10T15:03:14.688Z</modification><creation>2022-02-10T15:03:14.688Z</creation></dates><accession>S-EPMC8183405</accession><cross_references><pubmed>33769671</pubmed><doi>10.15252/embr.202052079</doi></cross_references></HashMap>